SCHEMBL645929

SCHEMBL645929

CCCS(=O)(=O)Nc1ccccc1Cc1ccc(N2CC(=O)NS2(=O)=O)c(O)c1

nearest known ligand 0.58

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 10/20 0.58
PTPN2 P17706 7/20 0.36
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PARP14 Q460N5 1/20 0.33
KCNA5 P22460 1/20 0.33
BRD4 O60885 1/20 0.33
PGAM1 P18669 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648527 0.95 PTPN1 (0.56) PTPN1PTPN2PARP14BRD4PGAM1
SCHEMBL12971498 0.94 PTPN1 (0.60) PTPN1PTPN2
SCHEMBL648987 0.90 PTPN1 (0.53) PTPN1PTPN2TP53GAAMAPT
SCHEMBL649018 0.90 PTPN1 (0.52) PTPN1PTPN2TP53GAAMAPT
SCHEMBL647629 0.89 PTPN1 (0.64) PTPN1PTPN2
SCHEMBL648664 0.89 PTPN1 (0.55) PTPN1PTPN2TP53GAAMAPT
SCHEMBL646413 0.88 PTPN1 (0.56) PTPN1PTPN2PARP14PGAM1
SCHEMBL646154 0.88 PTPN1 (0.60) PTPN1PTPN2
SCHEMBL647690 0.88 PTPN1 (0.58) PTPN1PTPN2TP53MAPTBRD4
SCHEMBL646568 0.87 PTPN1 (0.52) PTPN1PTPN2GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1963294-B1 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) NOVARTIS AG (CH) 2012-10-10 EP claimed
US-8119666-B2 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) NOVARTIS AG (CH) 2012-02-21 US claimed
US-8119666-B2 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) NOVARTIS AG (CH) 2012-02-21 US disclosed